The Patent Finder

Evofem Biosciences, Inc.

13 patents currently held · Updated Nov 16, 2026
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Sep 2035
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 27, 2026
    The maintenance fee for Secnidazole for use in the treatment of bacterial vaginosis (US 11,684,607) comes due Dec 27, 2026. Unpaid by Jun 28, 2027, it lapses early.
  • 1 fee due Jan 2, 2027
    The maintenance fee for Secnidazole for use in the treatment of bacterial vaginosis (US 10,335,390) comes due Jan 2, 2027. Unpaid by Jul 2, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 term has ended since Aug 18, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 10,335,390Secnidazole for use in the treatment of bacterial vaginosis
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,682,338Secnidazole for use in the treatment of bacterial vaginosis
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,849,884Secnidazole for use in the treatment of bacterial vaginosis
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,857,133Secnidazole for use in the treatment of bacterial vaginosis
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,000,507Secnidazole for use in the treatment of bacterial vaginosis
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,000,508Secnidazole for use in the treatment of trichomoniasis
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,020,377Secnidazole for use in the treatment of bacterial vaginosis
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,324,721Secnidazole for use in the treatment of trichomoniasis
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,602,522Secnidazole for Use in the Treatment of Sexually Transmitted Infection
In force
 · Low confidence
In forceLow confidence
US 11,684,607Secnidazole for use in the treatment of bacterial vaginosis
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 13 patents shown.
Pro members see all 13.
Pro members: see all 13 patents
Also on record, not counted in the 13: 1 patent in force now held by others · 1 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited